HELIOS: Phase 3 trial of ibrutinib with bendamustine and rituximab for relapsed/refractory CLL | Dr Jacqueline Barrientos at Annual Meeting 2015

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Jacqueline Barrientos, MD, discusses the interim analysis of the randomised, double-blind, placebo-controlled, phase 3 HELIOS trial, which evaluated ibrutinib, a Bruton’s tyrosine kinase inhibitor, combined with bendamustine and rituximab (BR) versus vs BR plus placebo in patients with previously treated chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma.

European Medical Journal

Website: http://emjreviews.com/
Twitter: https://twitter.com/EMJReviews
Facebook: https://www.facebook.com/emjreviews